Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Quantum Genomics S.A. is a biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases, particularly targeting resistant hypertension and heart failure. Founded in 2005 and headquartered in Paris, France, the company addresses unmet medical needs by advancing a new class of drugs based on proprietary mechanisms in cardiovascular pharmacology. Quantum Genomics is noted for its lead drug candidate, firibastat, which is designed to treat patients whose conditions are not adequately managed by existing therapies. The company's research and development efforts are driven by a commitment to scientific innovation and addressing significant gaps in current treatment paradigms. With a strong emphasis on late-stage clinical trials and regulatory strategy, Quantum Genomics collaborates with global partners to bring novel solutions to market. Its work plays a meaningful role in the healthcare and biotechnology sectors, aiming to improve outcomes for patients with life-threatening cardiovascular conditions.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€0.00
▼ -100.0% YoY
Net Income (TTM)
-€9M
▼ -180.4% YoY
Op. Margin
—
ROIC
-40.18%
▲ +4.4pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
€2M
Cash & Equiv.
€301K
Continue Research